• Justin W Walker and Theodore J Cios.
• Department of Anesthesiology and Perioperative Medicine, Division of Cardiovascular Anesthesiology, Penn State Health Milton S. Hershey Medical Center, Hershey, PA.
• J. Cardiothorac. Vasc. Anesth. 2021 Jul 1; 35 (7): 2194-2200.

AbstractSurgical ventricular remodeling (SVR) is an invasive method of treating patients with heart failure who also have ischemic cardiomyopathy and reduced ejection fraction (EF). Introduced in the mid-1980s, this technique was met with varying success and relatively high morbidity and mortality despite its theoretical benefits. The development of the BioVentrix Revivent TC System (BioVentrix, Inc., San Ramon, CA) as a less-invasive method of surgical ventricular remodeling has created a novel, multidisciplinary approach to heart failure management, which necessitates multiple subspecialties. Currently in the trial phase in the United States and widely used in Europe, the positive results to date appear promising for the rapid adoption of this procedure. For the cardiac anesthesiologist, a thorough understanding of the patient population, procedural goals, and intraoperative management is essential. This overview discusses the advancement in surgical ventricular remodeling, the pertinent surgical steps of the BioVentrix Revivent TC System placement, and specific anesthetic considerations for this novel procedure.Copyright © 2021 Elsevier Inc. All rights reserved.

14 keywords...

hide…